These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31041639)

  • 1. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
    Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
    Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
    Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
    [No Abstract]   [Full Text] [Related]  

  • 6. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
    Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
    Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
    J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
    J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
    Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.
    Saraiya N; Yopp AC; Rich NE; Odewole M; Parikh ND; Singal AG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):127-137. PubMed ID: 29851093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
    J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
    Nakano M; Koga H; Ide T; Kuromatsu R; Hashimoto S; Yatsuhashi H; Seike M; Higuchi N; Nakamuta M; Shakado S; Sakisaka S; Miuma S; Nakao K; Yoshimaru Y; Sasaki Y; Oeda S; Eguchi Y; Honma Y; Harada M; Nagata K; Mawatari S; Ido A; Maeshiro T; Matsumoto S; Takami Y; Sohda T; Torimura T
    Cancer Med; 2019 May; 8(5):2646-2653. PubMed ID: 30900818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.